Paraneoplastic rheumatic syndromes

Research output: Article

36 Citations (Scopus)

Abstract

Paraneoplastic symptoms caused by a malignancy but not directly related to tumour invasion are the result of a wide variety of tumour-derived biologic mediators, such as hormones, peptides, antibodies, cytotoxic lymphocytes, autocrine and paracrine mediators. Recognition of paraneoplastic syndromes is important, as it may lead to an early diagnosis of cancer. On the other hand, the clinical severity of the symptoms can be used as a guide to the extent of response to underlying tumour therapy. The quality of life of the patient is affected, therefore the palliative treatment of paraneoplasia is very important.

Original languageEnglish
Pages (from-to)376-382
Number of pages7
JournalRheumatology International
Volume26
Issue number5
DOIs
Publication statusPublished - márc. 2006

Fingerprint

Paraneoplastic Syndromes
Neoplasms
Peptide Hormones
Palliative Care
Early Detection of Cancer
Quality of Life
Lymphocytes
Antibodies
Therapeutics

ASJC Scopus subject areas

  • Rheumatology

Cite this

Paraneoplastic rheumatic syndromes. / András, C.; Csiki, Zoltán; Ponyi, A.; Illés, A.; Dankó, K.

In: Rheumatology International, Vol. 26, No. 5, 03.2006, p. 376-382.

Research output: Article

@article{5702a1dd5540408bbc59193e6a83d0ea,
title = "Paraneoplastic rheumatic syndromes",
abstract = "Paraneoplastic symptoms caused by a malignancy but not directly related to tumour invasion are the result of a wide variety of tumour-derived biologic mediators, such as hormones, peptides, antibodies, cytotoxic lymphocytes, autocrine and paracrine mediators. Recognition of paraneoplastic syndromes is important, as it may lead to an early diagnosis of cancer. On the other hand, the clinical severity of the symptoms can be used as a guide to the extent of response to underlying tumour therapy. The quality of life of the patient is affected, therefore the palliative treatment of paraneoplasia is very important.",
keywords = "Paraneoplasia, Rheumatic syndromes",
author = "C. Andr{\'a}s and Zolt{\'a}n Csiki and A. Ponyi and A. Ill{\'e}s and K. Dank{\'o}",
year = "2006",
month = "3",
doi = "10.1007/s00296-005-0005-3",
language = "English",
volume = "26",
pages = "376--382",
journal = "Rheumatology International",
issn = "0172-8172",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Paraneoplastic rheumatic syndromes

AU - András, C.

AU - Csiki, Zoltán

AU - Ponyi, A.

AU - Illés, A.

AU - Dankó, K.

PY - 2006/3

Y1 - 2006/3

N2 - Paraneoplastic symptoms caused by a malignancy but not directly related to tumour invasion are the result of a wide variety of tumour-derived biologic mediators, such as hormones, peptides, antibodies, cytotoxic lymphocytes, autocrine and paracrine mediators. Recognition of paraneoplastic syndromes is important, as it may lead to an early diagnosis of cancer. On the other hand, the clinical severity of the symptoms can be used as a guide to the extent of response to underlying tumour therapy. The quality of life of the patient is affected, therefore the palliative treatment of paraneoplasia is very important.

AB - Paraneoplastic symptoms caused by a malignancy but not directly related to tumour invasion are the result of a wide variety of tumour-derived biologic mediators, such as hormones, peptides, antibodies, cytotoxic lymphocytes, autocrine and paracrine mediators. Recognition of paraneoplastic syndromes is important, as it may lead to an early diagnosis of cancer. On the other hand, the clinical severity of the symptoms can be used as a guide to the extent of response to underlying tumour therapy. The quality of life of the patient is affected, therefore the palliative treatment of paraneoplasia is very important.

KW - Paraneoplasia

KW - Rheumatic syndromes

UR - http://www.scopus.com/inward/record.url?scp=33644616691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644616691&partnerID=8YFLogxK

U2 - 10.1007/s00296-005-0005-3

DO - 10.1007/s00296-005-0005-3

M3 - Article

C2 - 16091919

AN - SCOPUS:33644616691

VL - 26

SP - 376

EP - 382

JO - Rheumatology International

JF - Rheumatology International

SN - 0172-8172

IS - 5

ER -